Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 12
Submit an article Journal homepage
311
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement

Fateeha Furqana Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Grace Watsona Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Felipe Samaniegoa Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Luis E. Fayada Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Rashmi Kanagal-Shamannab Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0001-7829-5249View further author information
ORCID Icon,
Michael W. Morrisona Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Philip A. Thompsonc Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Raphael E. Steinera Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0003-3717-3629View further author information
ORCID Icon,
Linda Chid Department of Neuro-Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Bouthaina Dabajae Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Chelsea C. Pinnixe Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0003-3982-3664View further author information
ORCID Icon,
Sattva S. Neelapua Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Loretta J. Nastoupila Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
&
Paolo Stratia Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
View further author information
 show all
Pages 2980-2984 | Received 17 Apr 2020, Accepted 27 Jun 2020, Published online: 10 Jul 2020

References

  • Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
  • Pophali PA, Thanarajasingam G, Pulido J, et al. Low grade b-cell non-Hodgkin lymphomas (NHL) involving the central nervous system (CNS): an analysis from the National Cancer Database (NCDB). J Clin Oncol. 2017;35(15_suppl):e13083–e13083.
  • Ayanambakkam A, Ibrahimi S, Bilal K, et al. Extranodal marginal zone lymphoma of the central nervous system. Clin Lymphoma Myeloma Leuk. 2018;18(1):34–37.e38.
  • Bayraktar S, Stefanovic A, Montague N, et al. Central nervous system manifestations of marginal zone B-cell lymphoma. Ann Hematol. 2010;89(10):1003–1009.
  • de la Fuente MI, Haggiagi A, Moul A, et al. Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences. Leuk Lymphoma. 2017;58(4):882–888.
  • Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017;129(16):2224–2232.
  • FDA. IMBRUVICA. (ibrutinib) prescribing information. 2017.
  • Wanquet A, Birsen R, Lemal R, et al. Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia. Blood. 2016;127(19):2356–2358.
  • Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1997;15(3):1110–1117.
  • Cheson BD, Fisher RI, Barrington SF. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
  • Chihara D, Fowler NH, Oki Y, et al. Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis. Oncotarget. 2018;9(48):28897–28902.
  • Sunderland AJ, Steiner RE, Al Zahrani M, et al. An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement. Cancer Med. 2020;9(2):663–670.
  • Iwamoto FM, DeAngelis LM, Abrey LE. Primary dural lymphomas: a clinicopathologic study of treatment and outcome in eight patients. Neurology. 2006;66(11):1763–1765.
  • Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(6):833–843.e835.
  • Bernard S, Goldwirt L, Amorim S, et al. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. Blood. 2015;126(14):1695–1698.
  • Castillo JJ, Itchaki G, Paludo J, et al. Ibrutinib for the treatment of bing-neel syndrome: a multicenter study. Blood. 2019;133(4):299–305.
  • Kim T, Choi HY, Lee HS, et al. Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL). BMC Cancer. 2018;18(1):729.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.